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Abstract. 
BACKGROUND: Early detection of non responders to hepatitis C therapy limits 
unnecessary exposure to treatment and its side effects.  A recent algorithm combining 
baseline anti-NS4a antibodies and on treatment quantitative PCR identified non 
responders to a combination of interferon and ribavirin after 1 week of treatment.  
AIM: To validate a stopping rule based on baseline anti-NS4a antibody levels and early 
on treatment virological response in treatment naive genotype 1 chronic hepatitis C 
patients treated with the current standard pegylated interferon and ribavirin 
combination therapy.   
METHODS:  Eighty-nine (89) genotype 1 patients from the DITTO study treated for 48 
weeks with standard 180 µg PEG-IFN-α-2a weekly and ribavirin 1000-1200 mg daily, 
were analysed.  Baseline anti-NS4a antibody ELISA (NS4a AA 1687-1718) was 
performed on pre-treatment serum.  HCV-RNA was assessed at day 0, 1, 4, 7, 8, 15,  
22, 29, week 6, 7, 8, 10, 12 and 6 weekly thereafter until end of treatment.  Multiple 
regression logistic analysis was performed. 
RESULTS:  Overall 54/89 (61%) patients achieved sustained viral response.  A baseline 
anti-NS4a antibody titre <1/1250 correlated with absence of favourable initial viral 
decline according to variable response types (p= 0.015).  The optimal algorithm was 
developed using the combination of the absence of anti-NS4a Ab (<1/1250) at baseline 
and the presence of a viral load ≥ 100.000 IU/ml at week 4.  This algorithm has a 
specificity of 43% and negative predictive value of 100% to detect non response to 
standard PEG-IFN-α-2a and ribavirin therapy at week 4  of therapy (intention to treat 
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analysis).   
CONCLUSIONS: The decision to stop therapy in genotype 1 chronic hepatitis C patients 
treated with PEG-IFN-α-2a and ribavirin can be confidently made after 4 weeks of 
treatment based on the absence of baseline anti-NS4a Ab and a week 4 HCV-RNA above 
100.000 IU/ml. 
 
 
Keywords: hepatitis C; HCV-RNA; peginterferon alfa-2a; ribavirin; stopping rule; anti 
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Introduction. 
 
Pegylated interferon-α-2a and ribavirin (RBV) combination therapy induces a sustained 
virological response (SVR) in only half of the genotype 1 infected chronic hepatitis C 
patients.1  Accurate early recognition of those patients who will not clear the HCV 
infection despite a full 48 week treatment course allows early treatment discontinuation 
limiting unnecessary exposure to potential side effects.  The absence of a more than 2 
log drop from baseline viral load after 12 weeks of treatment detects  31% of non 
responder patients with a negative predictive value (NPV) of 97%.1, 2  A stopping rule 
that would identify more non responder patients earlier on during the treatment would 
limit further the side effects and costs of the treatment for these patients. 
Recently Desombere et al. developed a stopping algorithm based on the absence or 
presence of baseline anti-NS4a antibodies (Ab) and early on treatment viral load that 
detects non response with a NPV of 100% in a group of patients treated with standard 
interferon and RBV combination therapy.3   
Our aim was to develop a stopping rule with at least similar NPV and improved 
specificity in comparison to the current week 12 stopping rule, based on baseline anti-
NS4a serology status and early on treatment quantitative viral load in patients treated 
with peginterferon-α-2a and RBV combination therapy. 
 
Materials and Methods. 
The Dynamically Individualized Treatment of hepatitis C Infection and Correlates of 
Viral/Host dynamics (DITTO) HCV study group recruited 270 chronic hepatitis C patients 
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for an open label  phase 3 international multicenter trial.4  Treatment-naive patients 
with compensated liver disease and the following characteristics were eligible: positive 
test for anti-HCV antibody, HCV-RNA > 1000 IU/ml (Cobas Amplicor HCV Monitor v. 2.0 
assay, Roche Diagnostics, lower limit of detection 600 IU/ml), two serum alanine 
aminotransferase values above the upper limit of normal within 6 months of treatment 
initiation, and a pre-treatment (within previous 12 months) liver biopsy consistent with a 
diagnosis of chronic hepatitis C.  The major exclusion criteria were previously reported.4  
Patients were randomised after 6 weeks of combination therapy with peginterferon-α-2a 
and weight based RBV combination therapy according to initial viral kinetics of the first 4 
weeks to either individualised treatment or continued standard treatment until week 48. 
For this analysis the subset of 89 genotype 1 patients who completed at least 4 weeks 
of therapy in the standard treatment arm were analysed.  All patients were treated with 
weekly injections of 180 µg peginterferon-α-2a in combination with daily oral RBV at a 
dose of 1000 or 1200 mg depending of bodyweight below or above 75 kg.  All patients 
were motivated to continue treatment for the 48 week treatment period.  Treatment 
could be stopped at the discretion of the investigator if HCV-RNA was still positive after 
24 weeks of treatment. 
Labatory assessments.  HCV-genotyping was confirmed centrally at Erasmus MC 
University Medical Center Rotterdam by reverse hybridization (Inno LipA HCV II; 
Innogenetics, Gent, Belgium).  Baseline anti-NS4a ELISA was determined on a pre-
treatment serum sample (NS4a AA 1687-1718, horseradish peroxidise-labelled goat anti-
human IgG antibody; dilutions 1/10, 1/100, 1/250, 1/1250, 1/16250) in the CEVAC lab 
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in Ghent as described previously.3  HCV-RNA was determined centrally in Rotterdam 
with the Cobas Amplicor HCV Monitor v. 2.0 assay (Roche Diagnostics, lower limit of 
detection 600 IU/ml) at day 0, 1, 4, 7, 8, 15, 22, 29, week 6, 7, 8, 10 and 12 and 6 
weekly thereafter until end of treatment.  All samples that tested negative with the 
quantitative assay were retested with the Cobas Amplicor HCV Monitor v2.0 qualitative 
assay (Roche Diagnostics, lower limit of detection 50 IU/ml).  
Definition of response type: In the DITTO study Rapid Viral Response (RVR) was 
defined as a ≥2 log drop of HCV-RNA during the first 4 weeks and a second-phase 
decline ≥0.09 log/day.  Slow partial response (SPR) was defined as no RVR but a 
second-phase decline ≥0.09 log/day and (i) a ≥1 log drop of HCV-RNA during the first 4 
weeks or (ii) a ≥0.6 log drop of HCV-RNA during the first 4 weeks and a first-phase 
decline of ≥0.5 log.  SVR was defined as negative qualitative HCV-RNA <50 IU/ml at 24 
weeks after the end of treatment (week 72).  
Study end points and objectives. 
The primary objective of this study was to develop a stopping rule that reliably detects 
non responder patients during the first weeks of treatment based on the absence of 
pre-treatment anti NS4a Ab and the presence of a rapid on treatment HCV-RNA decline. 
Two items were considered of paramount importance in the development of the 
stopping rule: NPV and Specificity.  The NPV of a stopping rule reflects the probability 
that the algorithm indeed predicts a true “non-response”, or in other words how sure 
one can be that no potential SVR patients will be lost by applying the early stopping 
rule.  The specificity (SPEC) depicts the fraction of all non-responding patients that will 
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indeed be identified by the prediction criteria.  The goal is the highest possible 
specificity with a NPV of 100%.  For this study we aimed to develop a stopping rule that 
could detect at least a similar proportion of non responders as the current week 12 2 log 
rule, but to detect these patients at an earlier stage during treatment while maintaining 
excellent NPV.  
Statistical analysis. 
Multiple logistic regression analysis was used to explore a possible correlation between 
non sustained virological response, baseline anti-NS4a Ab titre and viral load at baseline 
and day 0, 1, 4, 7, 8, 15, 22, 29.  All analyses were performed as intention to treat 
analysis, categorizing patients with missing week 72 data as non sustained virological 
patients.  Receiver Operating Characteristic curves and Akaike Information Criteria were 
used to investigate the non-inferiority of specificity and NPV of a possible new stopping 
algorithm with the current week 12 2 log rule specificity and NPV.  All analyses were 
performed using SPSS® 12.0 statistical software (SPSS Inc., Chicago, Illinois, US). 
 
Results. 
Patient characteristics.  The study population (n=89) consisted genotype 1 infected 
chronic hepatitis C patients with  a mean age of 41 years (20-66), predominantly of 
Caucasian origin.  Sixty-four percent of patients (57/89) had a high baseline viremia of 
≥ 0.8 x 106 IU/ml and the median viremia at baseline in this study group was 1.38 x 106 
IU/ml.  Ten percent of patients had a baseline viremia < 105 IU/ml.  Cirrhosis, defined 
as an Ishak score of 5 or 6, was present in 10% of the patients (Table 1).  SVR in this 
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study group with a high baseline viremia was 61% (54/89) when treated with a 
standard 48 weeks peginterferon-α-2a and RBV combination therapy (intention to treat 
analysis)..  SVR was achieved in 39/47 (83%) and 14/30 (47%) of the patients showing 
RVR and SPR according to the DITTO response types, respectively.  35/89 patients had 
no SVR at week 72.  Of these 9/89 (10%) discontinued treatment prematurely prior to 
week 48.  15/89 (17%) did not achieve week 48 end of treatment virological response.  
Relapse occurred in the remaining 11/89 (12%) at week 72. 
 
Baseline anti-NS4a antibody levels.  Logistic regression analysis showed a 
correlation between baseline anti-NS4a Ab levels and the initial viral kinetics.  Patients 
with a baseline anti-NS4a Ab titre of <1/1250 displayed significantly fewer rapid viral 
responses or slow partial responses compared to patients with a baseline anti-NS4a Ab 
titre ≥ 1/1250 (p= 0.015 Chi-square) (Fig. 1).  There was no statistically significant 
correlation between baseline anti-NS4a Ab levels and HCV-RNA negativity at any time 
point of treatment or with the SVR status at end of follow-up. 
 
HCV-RNA at Week 4.  A single HCV-RNA value exceeding 105 IU/ml at week 4 was 
superior in detecting non responding patients early on during treatment (sensitivity 
96.3%, specificity 48.6%, PPV 74.3%, NPV 89.5%) than a 2 log HCV-RNA decline at this 
time point.  This parameter however lacked adequate NPV prohibiting its clinical 
application as stopping rule , since therapy would be incorrectly stopped  in 10.5% of 
patients. 
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HCV-RNA at week 12.  Evaluation of the current week 12 2 log stopping rule in this 
group showed a sensitivity of 100%, a specificity of 31%, a PPV of 69% and a NPV of 
100%, confirming previously reported values.1, 2  In this group of 89 patients, a stopping 
rule based on the absence of a week 12 HCV-RNA below 1600 IU/ml had the best 
specificity of 43% while maintaining a NPV of 100% to predict non response. 
 
Algorithm based on early HCV-RNA determination and baseline anti-NS4a 
antibody titer.  Multiple logistic regression analysis with the variables baseline anti-
NS4a Ab titre, HCV-RNA level and treatment duration was performed (Fig.2).  An 
algorithm could be developed based on a baseline anti-NS4a Ab titre of <1/1250 and 
the presence of a HCV-RNA ≥105 IU/ml after 4 weeks of treatment.  Patients who had 
week 4 HCV-RNA of ≥105 IU/ml and a baseline anti-NS4a Ab titre of < 1/1250 had no 
chance of achieving SVR with continued treatment.  This algorithm had a sensitivity of 
100%, specificity of 43%, PPV of 73% and NPV of 100% to detect non response to 
standard peginterferon-α-2a RBV combination therapy after 4 weeks of therapy 
(intention to treat analysis).  The performance of this stopping rule is similar in the 
group of 80/89 patients with a baseline HCV-RNA ≥105 IU/ml as all patients with a week 
4 HCV-RNA <105 IU/ml are to continue therapy with this rule (sensitivity 100%, 
specificity 43%, PPV 69%, NPV 100%).  Our week 4 stopping rule categorised 7 of the 
9/89 drop out patients as week 4 responders.  The week 4 algorithm has a sensitivity of 
100%, specificity of 50%, PPV of 81% and NPV of 100% in the 80/89 patients who 
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continued treatment until week 48.  It is hence fair to assume that the drop-out rate did 
not favour a positive bias towards the week 4 algorithm. 
The week 4 rule identified at least  a similar proportion of non sustained virological 
responders as the current week 12 2 log rule (specificity 43 vs 31 respectively, Receiver 
Operating Characteristic curves: Akaike Information Criteria 91.2 and 98.3 and Area 
Under the Curve 0.724 and 0.657 for the new week 4 and current week 12 algorithm 
respectively) and a NPV of 100% at an 8 week earlier time point.    Analysis of 
concordant and discordant results showed that all adherent week 12 2 log non sustained 
virological responders were identified by the week 4 algorithm.  Consecutive application 
of the new week 4 algorithm and by the current week 12 2 log rule would detect 51 % 
of non responders (18/35) after 12 weeks of treatment in this study group (Fig.3). 
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Discussion.  
The aim of this study was to develop a clinical applicable stopping rule that would allow 
earlier detection of non response compared to the current week 12 2 log stopping rule 
while maintaining a reliable NPV and detecting at least a similar proportion of non 
responder patients.  The combination of a low anti-NS4a Ab titer at baseline, correlating 
with a low likelihood of favourable initial viral kinetics, and HCV-RNA determination at 
week 4, constitutes a stopping rule with adequate NPV and specificity.  This stopping 
rule detects at least a similar proportion of non responders as the week 12 2 log rule, 
but does so 8 weeks earlier. 
Careful examination of the three variables used in this analysis, namely HCV-RNA level, 
treatment duration and baseline anti NS4a Ab titre, revealed the following trends.  The 
earlier the time point, the better the specificity and PPV but the worse the sensitivity 
and NPV for a given HCV-RNA cut-off or log decline value.  This translates into the 
clinical knowledge that the presence of early on treatment HCV-RNA negativity favours 
subsequent SVR but is not an absolute requirement since a number of patients who 
achieve HCV-RNA negativity later than week 4 still become sustained responders with 
continued treatment.  This prevents the development of a clinically relevant stopping 
algorithm based on a single qualitative HCV-RNA level alone before week 12.  In this 
cohort 96.3% of responder patients had a week 4 HCV-RNA below 105 IU/ml, the cut-off 
put forward in Desombere’s algorithm.3  In patients treated with pegylated interferon 
this cut-off has clinical relevance after 4 weeks treatment duration whereas in 
Desombere’s study in patients treated with short acting standard interferon this cut-off 
HCV week 4 stopping rule  Orlent 12 
value appeared to be useful already after one week of therapy.  The NPV of 90% of the 
week 4 HCV-RNA cut-off of 105 IU/ml is insufficient to be used as a reliable stopping 
rule.  We were able to increase the NPV of an early on treatment qualitative HCV-RNA 
level by adding a baseline parameter to our algorithm.  Our findings corroborate those 
of Desombere et al.3  in that decreasing baseline anti-NS4a Ab levels correlate with the 
absence of a favourable initial viral response to peginterferon and RBV combination 
treatment.  The mechanism underlying this association is unclear at present.  It has 
recently been shown that the HCV NS3/4a protease interferes with the innate immune 
response against HCV infection by abrogation of the RIG1 and TLR3 pathway.5-7  It has 
also been shown that interferon non responders have high baseline Interferon 
Stimulated Genes status (ISGs) without any further increase upon interferon 
administration compared to interferon responders.8  We speculate that the counteractive 
interaction of the  NS3/4a protease with the innate immune system and the ISGs 
response is abrogated in the presence of a high titer of anti-NS4a specific antibodies, 
resulting in both better innate response and more favourable viral response to 
exogenous administered interferon.   
Many baseline factors have been described that correlate with a lower probability to 
obtain SVR in genotype 1 patients with peginterferon and RBV treatment.  Amongst 
these high viral load, advanced fibrotic stage, afro-american descendance, high BMI and 
presence of steatosis are recognised baseline factors that make SVR less likely.9, 10  Low 
IP10 interferon gamma inducible protein11, 12, baseline homozygosity for the promoter 
diplopy of ACC-IL10 in non-hispanic caucasian patients13 , and IL28B CC genotype 
HCV week 4 stopping rule  Orlent 13 
regardless of descendance14, 15 correlate with a higher probability to achieve SVR in 
adherent patients.  The presence of baseline factors statistically in disfavour for SVR 
does not obviate the possibility to achieve SVR in a given patient completely. 
Withholding therapy on the basis of any of these parameters is thus unjustified and the 
need for early accurate on treatment detection of non response remains of paramount 
importance.  Our new week 4 stopping rule is based on the presence of a baseline 
factor that correlates with favourable initial viral kinetics on the one hand, baseline level 
of anti-NS4a Ab, and on treatment HCV-RNA on the other hand as direct reflection of 
interferon response and indirect reflection of patient adherence.  Our new paradigm will 
be easy to apply in current practice since week 4 HCV-RNA determinations have become 
custom management in most centres.  This algorithm has a higher specificity and hence 
detects a larger proportion of non responding patients early on during treatment 
compared to a recently proposed stopping rule that is based on the absence of a 2 log 
viral decline and week 4 HCV-RNA >5.5 log IU/ml16.  It is important that the new, week 
4 stopping rule has a 100% NPV and will thus stop therapy only in true non responders.  
All patients in this study were offered treatment for 48 weeks of treatment, irrespective 
of the week 12 HCV-RNA results, with the possibility to stop treatment if week 24 HCV-
RNA was positive.  The new stopping rule is therefore valid for the true occurrence of 
SVR or no SVR. 
Our findings are based on data of a moderate size group and ideally are to be validated 
in the framework of larger patient groups.  It is likely that our stopping rule will need 
adaptations with the advent of new future direct antiviral agent treatment regimes , 
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since the majority of genotype 1 patients treated with these regimes have undetectable 
HCV-RNA after 4 weeks of combination therapies with these new agents.17, 18 
In conclusion, a baseline anti-NS4a Ab titer of < 1/1250 in combination with a week 4 
PCR ≥105 IU/ml reliably detects non response to 48 weeks of peginterferon and RBV 
therapy with a negative predictive value of 100% and does so 8 weeks earlier than the 
current week 12 2 log rule. 
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Appendix: 
 
Steering Committee members of the DITTO-HCV Study are: Carlo Ferrari (Divisione di 
Malattie Infettive, Azienda Ospedaliera di Parma, Parma, Italy), Avidan U. Neumann 
(Faculty of Life Sciences, Bar-Ilan UniversityRamat-Gan , Israel), Jean-Michel Pawlotsky 
(Department of Bacteriology and Virology, Hopital Henri Mondor - Université Paris XII, 
Creteil, France),  Solko W. Schalm and Stefan Zeuzem (Medizinische Klinik II, Klinikum 
der Johann Wolfgang Goethe-Universitat, Frankfurt A.M., Germany). 
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Tables. 
Table 1:  Patient characteristics. 
 
 
Male/Female (%)  70/30 
Mean age in years (range)  41 (20-66) 
Caucasian (%) 97 
Mean baseline ALT (xULN) 2.9 
Median HCV-RNA (IU/ml) 1.380.000 
# of pts with HCV-RNA >800.000 IU/ml 57/89 (64 %) 
# of pts with HCV-RNA <100.000 IU/ml  9/89 (10 %) 
# of pts with Ishak fibrosis stage 5-6  7/77 (9%) 
# of pts with SVR 54/89 (61%) 
 
HCV week 4 stopping rule  Orlent 17 
Figure Legends. 
 
Figure 1:  Baseline anti-NS4a antibody titer (1/n) and early on treatment 
response type. 
A baseline anti-NS4a Ab titer ≥1/1250 correlates  with the occurrence of more RVR/SPR versus 
absence of  RVR/SPR  in patients  with a baseline anti-NS4a Ab <1/1250 (RVR: Rapid Viral 
Respnose, SPR Slow Partial Response) (p= 0.015). 
 
Figure 2:  Multiple logistic regression analysis. 
Negative Predictive Value and Specificity of a new algorithm combining early PCR and baseline 
anti-NS4a serology: the addition of ascending baseline anti-NS4a antibody titer <1/1250 to a 
PCR cut-off of 100.000 IU/ml at week 4 creates a stopping rule with a  specificity of 43% and a 
NPV of 100% (ITT analysis). 
 
Figure 3:  Week 4 stopping rule: 
Patients with a baseline anti-NS4a antibody titer <1/1250 and a week 4 viremia ≥100.000 
IU/ml have no chance of obtaining SVR with continued treatment and can be advised to stop 
therapy. 
HCV week 4 stopping rule  Orlent 18 
Figure 1:  Baseline anti-NS4a antibody titer and early on treatment response type. 
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Figure 2:  Multiple logistic regression analysis. 
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Figure 3: Week 4 stopping rule. 
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